TRANSVAC-DS – Design Study for a European Vaccine Infrastructure

Project Acronym TRANSVAC-DS
Funding Program H2020
Budget 1,879,216.25
Starting-ending date June 1, 2020 – Mat 31, 2022

Two infrastructure projects – TRANSVAC1 and TRANSVAC2 – have been funded by the European Commission which – through the provision of state-of-the-art scientific-technical vaccine development services, technical training, and innovative vaccine research and development – have provided very significant support to European vaccine researchers and developers. Support has been and is being provided to the development of human and veterinary prophylactic and therapeutic vaccines.  

The TRANSVAC-DS project builds on the outstanding success of the two abovementioned infrastructure projects and proposes the establishment of a truly sustainable European vaccine infrastructure, which will build upon the lessons learned, activities and achievements. The main output is a conceptual design report that describe in detail the maturity of the concept and be the basis for the establishment of a permanent and sustainable vaccine infrastructure of direct relevance to and benefit for Europe and further afield. As part of the design report, a five-year business plan will be delivered together with an implementation plan that will guide the further establishment of a sustainable European vaccine infrastructure.  

See the poster here.

TRANSVACDS Consortium  

The twenty-five partners in the TRANSVAC-DS consortium represent ten EU Member States and Associated Countries and include leading organisations from the European vaccine R&D field. 

The role of EATRIS is focused on ensuring that the project aligns with the strategic objectives set out and on designing a strong governance structure for the R&D infrastructure. Ensuring that the available budgets/financial commitments are identified and that the scope and the outputs of the project are clear, EATRIS contributes in the preparation of financing plans and long-term sustainability and in the integration and coordination of the operations with existing biomedical research infrastructures.